Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have received an average recommendation of “Moderate Buy” from the ten analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $38.3333.

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus dropped their target price on Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, June 1st. HC Wainwright reiterated a “buy” rating on shares of Oculis in a research report on Thursday, June 11th. JPMorgan Chase & Co. lowered their price objective on Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Guggenheim cut their target price on shares of Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Friday, July 17th.

Oculis Stock Performance

OCS stock opened at $10.84 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The company has a 50 day moving average price of $14.54 and a 200 day moving average price of $22.88. Oculis has a fifty-two week low of $10.52 and a fifty-two week high of $34.47. The stock has a market capitalization of $628.50 million, a PE ratio of -5.09 and a beta of 0.44.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. Analysts forecast that Oculis will post -2.27 EPS for the current year.

Hedge Funds Weigh In On Oculis

Hedge funds and other institutional investors have recently bought and sold shares of the business. Gildi lifeyrissjodur acquired a new stake in Oculis during the 4th quarter worth $50,250,000. Aberdeen Group plc lifted its stake in shares of Oculis by 39.4% in the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after purchasing an additional 493,827 shares during the period. Perceptive Advisors LLC acquired a new position in shares of Oculis in the 4th quarter valued at $9,862,000. SR One Capital Management LP boosted its position in shares of Oculis by 98.8% in the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after purchasing an additional 318,522 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its position in shares of Oculis by 152.3% in the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after purchasing an additional 200,000 shares during the last quarter. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.